Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01336569 · ClinicalTrials.gov registry record · Phase 4
Safety and Efficacy of Changing to DuoTrav in Patients Uncontrolled on Timolol
A Phase 4 study, sponsored by Alcon Research.
- Completed
- Registry status
- Phase 4
- Development phase
- 50
- Enrollment target
NCT01336569 is a Phase 4 study that has completed, run by Alcon Research. The registered enrollment target is 50 participants.
The verdict
NCT01336569, a Phase 4 study, has completed, sponsored by Alcon Research.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 50 participants
- Enrollment target
Study Summary
The purpose of this study was to assess the safety and intraocular pressure (IOP)-lowering efficacy of changing to DuoTrav® from prior timolol 0.5% monotherapy in participants with open-angle glaucoma or ocular hypertension.
Interventions
- DRUG Travoprost 0.004%/timolol maleate 0.5% fixed combination
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2011-02 |
| Est. Completion | 2012-03 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01336569
The ClinicalTrials.gov registry entry for NCT01336569 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alcon Research, which has 275 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Travoprost 0.004%/timolol maleate 0.5% fixed combination is the first listed.
NCT01336569 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01336569 about?
NCT01336569 is a clinical study titled "Safety and Efficacy of Changing to DuoTrav in Patients Uncontrolled on Timolol". The purpose of this study was to assess the safety and intraocular pressure (IOP)-lowering efficacy of changing to DuoTrav® from prior timolol 0.5% monotherapy in participants with open-angle glaucoma or ocular hypertension.
What is the current status of trial NCT01336569?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 50 participants. The study started on 2011-02. Estimated completion is 2012-03.
What interventions are being tested in trial NCT01336569?
The interventions under investigation include: Travoprost 0.004%/timolol maleate 0.5% fixed combination (DRUG).
Who is sponsoring clinical trial NCT01336569?
This trial is sponsored by Alcon Research, which has 275 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.